stockportfolio.pro
BrainsWay Ltd. (BWAY)
Healthcare · Medical Devices · NasdaqGM
BrainsWay Ltd. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $27.18M | $31.79M | $41.02M | $52.23M |
| Gross profit | $20.05M | $23.48M | $30.58M | $39.39M |
| Net income | $-13.35M | $-4.20M | $2.92M | $7.63M |
| Net margin | -49.1% | -13.2% | 7.1% | 14.6% |
Source: BrainsWay Ltd. SEC filings (10-K).
What growth is priced into BWAY stock?
At today's market cap of $598.98M, BrainsWay Ltd. is priced for free-cash-flow growth of about 16% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.27M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of BrainsWay Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BWAY in your portfolio →
BrainsWay Ltd. financial history by metric
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BrainsWay Ltd. — frequently asked questions
What is BrainsWay Ltd.'s revenue?
BrainsWay Ltd. (BWAY) reported revenue of $52.23M for fiscal year 2025, up 27.3% from the prior year, according to its SEC filings.
Is BrainsWay Ltd. profitable?
Yes. BWAY earned net income of $7.63M in fiscal 2025, a net margin of 14.6%.
What is BWAY's P/E ratio?
BrainsWay Ltd. trades at a price-to-earnings ratio of about 67.9 based on the latest data in our nightly-refreshed cache.
How fast is BrainsWay Ltd. growing?
BWAY's revenue grew at roughly 24.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BrainsWay Ltd. have?
As of fiscal year 2025, BWAY carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BrainsWay Ltd.'s gross margin?
BWAY's gross margin was 75.4% in fiscal 2025 — gross profit of $39.39M on revenue of $52.23M.
What is BrainsWay Ltd.'s market cap?
BrainsWay Ltd. (BWAY) has a market capitalization of about $598.98M, based on the latest data in our nightly-refreshed cache.
When does BrainsWay Ltd.'s fiscal year end?
BWAY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BWAY stock?
At today's market cap of $598.98M, BrainsWay Ltd. is priced for free-cash-flow growth of about 16% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.27M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from BrainsWay Ltd.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.